• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    SC 13G 1 pavs_sc13g.htm FORM SC 13G pavs_sc13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO.       )*

     

    Paranovus Entertainment Technology Ltd.

    (Name of Issuer)

     

    Class A Ordinary Shares

    (Title of Class of Securities)

     

    G4289N205

    (CUSIP Number)

     

    August 7, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     

    ☐

    Rule 13d-1(b)

     

     

     

     

    ☒

    Rule 13d-1(c)

     

     

     

     

    ☐

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. G4289N205 

     

    1

    Name of Reporting Person

     

    Beta Vortex Limited

    2

    Check the Appropriate Box if a Member of a Group

    (a)   ☐

    (b)   ☐ 

    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    Hong Kong, China

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5

    Sole Voting Power

     

     

    6

    Shared Voting Power

     

    4,600,000 (1)

    7

    Sole Dispositive Power

     

     

    8

    Shared Dispositive Power

     

    4,600,000 (1)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,600,000 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares 

     

    ☐

    11

    Percent of Class Represented by Amount in Row 9

     

    6.89% (2)

    12

    Type of Reporting Person

     

    CO

    ______________

    (1)

    Represents 4,600,000 Class A ordinary shares of the Issuer, par value of $0.01 per share (“Class A Ordinary Shares”), held indirectly by Xin Zhong through Beta Vortex Limited.

    (2)

    The beneficial ownership percentage is calculated based on 66,724,675 Class A Ordinary Shares of the Issuer issued and outstanding as of November 19, 2024.

     

     

     

     

    CUSIP No. G4289N205  

     

    1

    Name of Reporting Person

     

    Xin Zhong

    2

    Check the Appropriate Box if a Member of a Group

    (a)   ☐

    (b)   ☐ 

    3

    SEC Use Only 

     

     

    4

    Citizenship or Place of Organization

     

    China

      

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5

    Sole Voting Power

     

    4,600,000 (1)

    6

    Shared Voting Power

     

     

    7

    Sole Dispositive Power

     

    4,600,000 (1)

    8

    Shared Dispositive Power

     

     

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    4,600,000 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares 

     

    ☐

    11

    Percent of Class Represented by Amount in Row 9

     

    6.89% (1)

    12

    Type of Reporting Person

     

    IN

    ______________

    (1)

    Represents 4,600,000 Class A Ordinary Shares held indirectly by Xin Zhong through Beta Vortex Limited.

    (2)

    The beneficial ownership percentage is calculated based on 66,724,675 Class A Ordinary Shares of the Issuer issued and outstanding as of November 19, 2024.

     

     

     

     

    ITEM 1.

     

    (a)

    Name of Issuer:

     

     

     

     

    Paranovus Entertainment Technology Ltd.

     

    (b)

    Address of Issuer’s Principal Executive Offices:

     

     

     

     

    250 Park Avenue, 7th Floor

    New York, NY 10177

     

    ITEM 2.

     

    (a)

    Name of Person Filing:

     

     

     

     

    Beta Vortex Limited and Xin Zhong (the “Reporting Persons”)

     

    (b)

    Address of Principal Business Office, or if None, Residence:

     

     

     

     

    Flat/Rm A 12/F Zj 300, 300 Lockhart Road, Wan Chai, Hong Kong.

     

    (c)

    Citizenship:

     

     

     

     

    China

     

    (d)

    Title of Class of Securities:

     

     

     

     

    Class A Ordinary Shares

     

    (e)

    CUSIP Number

     

    G4289N205

     

     

     

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    Not Applicable.

     

    ITEM 4. OWNERSHIP.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. 

     

    The information presented in the cover pages is incorporated by reference here.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    [Not applicable.]

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    [Not applicable.]

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    [Not applicable.]

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    [Not applicable.]

     

    ITEM 10. CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
    2

     

     

    LIST OF EXHIBITS

     

    Exhibit No.

     

    Description

    1

     

    Joint Filing Agreement

     

     
    3

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 26, 2024

     

     

     

    Beta Vortex Limited

     

     

     

     

     

     

    By:

    /s/ Xin Zhong

     

     

     

    Name: Xin Zhong

     

     

     

    Title: Director

     

     

     

     

     

     

     

    /s/ Xin Zhong

     

     

     

    Name: Xin Zhong

     

     

     
    4

     

    Get the next $PAVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    SEC Filings

    View All

    Amendment: SEC Form 20-F/A filed by Paranovus Entertainment Technology Ltd.

    20-F/A - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    8/7/25 4:17:13 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 20-F filed by Paranovus Entertainment Technology Ltd.

    20-F - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    8/4/25 4:31:21 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form NT 20-F filed by Paranovus Entertainment Technology Ltd.

    NT 20-F - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    7/31/25 4:15:13 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Paranovus Entertainment Technology Limited Announces Receipt of a Bid Deficiency Notice from Nasdaq

    NEW YORK, July 15, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that on July 11, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq"), notifying the Company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's Class A ordinary shares on Nasdaq. Under the

    7/15/25 4:15:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Periodic Financial Reports Filing Rule

    NEW YORK, April 29, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that it has received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq"), dated April 25, 2025, notifying that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) (the "Rule"). The Nasdaq staff has determined that the Company complies with the Rule based on the Form 6-K furnished by the Company on April 24, 2025, disclosing its interim financial statements for the six-month ended September 30, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) and this filing delinquency matter i

    4/29/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Notification Letter Related to Late Filing of Form 6-K Reporting Interim Financial Information

    NEW YORK, April 10, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq"), dated April 9, 2025 (the "Deficiency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(2) because it did not timely file its Form 6-K (the "Filing") for the period ended September 30, 2024, reporting interim financial information for the six-month period there ended. In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Deficiency Letter to sub

    4/10/25 5:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Announces Receipt of a Bid Deficiency Notice from Nasdaq

    NEW YORK, July 15, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that on July 11, 2025, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq"), notifying the Company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's Class A ordinary shares on Nasdaq. Under the

    7/15/25 4:15:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Periodic Financial Reports Filing Rule

    NEW YORK, April 29, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that it has received a formal notification from the Nasdaq Stock Market LLC ("Nasdaq"), dated April 25, 2025, notifying that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) (the "Rule"). The Nasdaq staff has determined that the Company complies with the Rule based on the Form 6-K furnished by the Company on April 24, 2025, disclosing its interim financial statements for the six-month ended September 30, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5250(c)(2) and this filing delinquency matter i

    4/29/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Notification Letter Related to Late Filing of Form 6-K Reporting Interim Financial Information

    NEW YORK, April 10, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("PAVS" or the "Company"), (NASDAQ:PAVS) announced today that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq"), dated April 9, 2025 (the "Deficiency Letter"), notifying the Company that it is not in compliance with the requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(2) because it did not timely file its Form 6-K (the "Filing") for the period ended September 30, 2024, reporting interim financial information for the six-month period there ended. In accordance with Nasdaq Listing Rules, the Company has 60 calendar days from the date of the Deficiency Letter to sub

    4/10/25 5:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care